knowledge -WSS

knowledge

author：leisure time 2025-08-26 03:42:32 - browse：43

ITeos Therapeutics offered the first look at clinical data for its experimental cancer antibody that works by blocking the novel — and very buzzworthy — protein target called TIGIT.

The tumor-shrinking activity of the company’s drug, called EOS-448, was minimal but still comparable to early study data from competing TIGIT-targeted drugs in development, including ones from Roche and Merck.

iTeos presented the EOS-448 Phase 1 study results at the annual meeting of the American Association for Cancer Research on Saturday.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： ‘Oppenheimer’ and the risks of AI in health care

WSS

Fentanyl is making it harder to start addiction treatment

Reports of telehealth's death have been greatly exaggerated

What the US credit downgrade means for the economy, your finances

Biogen joins immunology wave with $1.15 billion acquisition of HI

Cue Health, Covid

Listen: More tumult at BIO & coercive care for sickle cell patients

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Malaria cases in Florida and Texas: Here’s what you need to know

Making the case for fair compensation in clinical trials

Duchenne breakthrough therapy leaves behind pioneering families

Adults seen as increasingly susceptible to measles

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

‘Oppenheimer’ and the risks of AI in health care

BioMarin wins approval for gene therapy to treat hemophilia A

Biogen joins immunology wave with $1.15 billion acquisition of HI

hotspot

Physician groups backed by private equity giant lobby on mergers

Adults seen as increasingly susceptible to measles

H5N1 virus can be tracked in retail milk, scientists say

NIH launches clinical trials and new research office for long Covid

Citing H5N1 threat, CDC urges peak flu monitoring this summer

ASCO eve: Let’s set the table for this year's meeting

hotspot

focus

hotspot

leisure time